Financial Performance - Consolidated total revenues for Q4 2024 were $183.6 million, a slight increase from $181.9 million in Q4 2023, with net income of $14.0 million compared to a net loss of $66.5 million in the prior year[3] - The operating loss for Q4 2024 was $33.1 million, an improvement from the operating loss of $69.1 million in Q4 2023[3] - Total revenues for the three months ended December 31, 2024, were $183.6 million, a slight increase from $181.9 million in the same period of 2023[14] - Operating loss narrowed to $33.1 million compared to a loss of $69.1 million in the same quarter last year[14] - Net income for the three months was $14.0 million, a recovery from a loss of $66.5 million in the previous year[14] - Basic income per share improved to $0.02 from a loss of $0.09 year-over-year[14] Revenue Breakdown - Revenue from pharmaceuticals in Q4 2024 was $37.4 million, down from $43.0 million in Q4 2023, primarily due to unfavorable foreign currency exchange fluctuations[3] - Revenue from services decreased to $103.1 million from $124.2 million year-over-year, representing a decline of approximately 16.8%[14] - Revenue from products also declined to $37.4 million from $43.0 million, a decrease of about 13.0%[14] - Revenue from the transfer of intellectual property increased significantly to $43.1 million from $14.7 million, marking a growth of approximately 194.5%[14] - Revenue from the transfer of intellectual property and other increased to $43.1 million in Q4 2024 from $14.7 million in Q4 2023, driven by a $23.8 million revenue from the BARDA contract[3] Expenses and Costs - Total costs and expenses increased to $82.6 million in Q4 2024 from $73.8 million in the prior-year period, primarily due to higher research and development expenses[3] - Total costs and expenses for the three months were $216.7 million, down from $251.0 million in the prior year[14] - Research and development expenses increased to $30.4 million from $19.4 million, reflecting a rise of approximately 56.7%[14] Cash and Financing - Cash, cash equivalents, and current restricted cash totaled $431.9 million as of December 31, 2024, compared to $95.9 million at the end of 2023[12] - The company repurchased $17.0 million of principal convertible notes for $25.0 million and an additional 10.9 million common shares for $16.5 million during Q4 2024[2] Strategic Initiatives - BioReference Health aims for profitability in 2025, having sold a portion of its laboratory testing businesses for $237.5 million to enhance growth and profitability[1] - Enrollment is underway in the Phase 1 trial for the MDX2001 treatment of solid tumor cancers, expected to enroll up to 45 patients[1] - OPKO received $51 million in additional funding under an existing BARDA contract to develop COVID multispecific antibodies and initiate an influenza program[1]

Core Insights - OPKO Health, Inc. reported financial results for Q4 and the full year 2024, highlighting a net income of $14.0 million compared to a net loss of $66.5 million in Q4 2023, indicating a significant turnaround in profitability [2][3][14] - Total revenues for Q4 2024 were $183.6 million, slightly up from $181.9 million in Q4 2023, with a notable increase in revenue from the transfer of intellectual property and other, which rose to $43.1 million from $14.7 million [3][14] - The company achieved a consolidated operating loss of $33.1 million in Q4 2024, an improvement from a loss of $69.1 million in the same quarter of the previous year [3][14] Financial Performance - Revenue from services in Q4 2024 was $103.1 million, down from $124.2 million in Q4 2023, primarily due to lower clinical test volumes following the sale of certain BioReference assets [8][14] - Revenue from products decreased to $37.4 million in Q4 2024 from $43.0 million in Q4 2023, attributed to unfavorable foreign currency exchange fluctuations [3][14] - Total costs and expenses for Q4 2024 were $216.7 million, down from $251.0 million in Q4 2023, reflecting cost-reduction initiatives and asset sales [8][14] Strategic Developments - OPKO's BioReference Health is targeting profitability for 2025 by reducing costs and enhancing productivity through innovation in specialty testing segments [2][3] - The company repurchased $17.0 million of principal convertible notes and 10.9 million common shares for $16.5 million during Q4 2024, part of a broader stock repurchase program [2][3] - OPKO received $51 million in additional funding from BARDA to develop COVID multispecific antibodies and initiate an influenza program, bringing total awarded funds to $110 million [2][3] Cash and Assets - As of December 31, 2024, OPKO reported cash, cash equivalents, and current restricted cash of $431.9 million, a significant increase from $95.9 million in the previous year [11][12] - Total assets increased to $2.2 billion in 2024 from $2.0 billion in 2023, indicating a solid financial position [11][12] Market Position - OPKO continues to leverage its proprietary technologies and partnerships, including a collaboration with Merck for an Epstein-Barr virus vaccine, which has commenced patient dosing in a Phase 1 trial [2][3] - The company is entitled to a share of gross profits from Pfizer's NGENLA, which is now available in all major markets, enhancing its revenue potential [2][3]

Core Viewpoint - Wall Street analysts predict OPKO Health will report a quarterly loss of $0.11 per share, reflecting a year-over-year decline of 22.2%, with anticipated revenues of $155.14 million, down 14.7% from the previous year [1]. Group 1: Earnings Estimates - The consensus EPS estimate for the upcoming quarter has remained unchanged over the past 30 days, indicating analysts' reassessment of their initial projections [1][2]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [2]. Group 2: Revenue Projections - Analysts forecast 'Revenues- Revenue from transfer of intellectual property and other' to reach $14.89 million, indicating a year-over-year increase of 1.3% [4]. - The consensus estimate for 'Revenues- Revenue from products' is $42.96 million, reflecting a slight decline of 0.1% from the year-ago quarter [4]. - 'Revenues- Revenue from services' is projected to reach $97.29 million, showing a significant year-over-year decrease of 21.7% [4]. Group 3: Stock Performance - Over the past month, OPKO Health shares have returned +17%, contrasting with the Zacks S&P 500 composite's -1.8% change [5]. - OPKO Health currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [5].

Core Viewpoint - OPKO Health, Inc. is set to report its operating and financial results for the three and twelve months ending December 31, 2024, on February 27, 2025, after U.S. market close [1] Group 1: Financial Reporting - The financial results will be discussed during a conference call and live audio webcast scheduled for February 27, 2025, at 4:30 p.m. Eastern time [1] - Participants are encouraged to pre-register for the conference call to receive a unique PIN for immediate access [2] Group 2: Access Information - A telephone replay of the conference call will be available until March 6, 2025, with specific dialing instructions provided [3] - A webcast replay will be accessible approximately one hour after the live conference call [3] Group 3: Company Overview - OPKO Health is a multinational biopharmaceutical and diagnostics company focused on establishing leading positions in rapidly growing markets through its expertise in discovery, development, and commercialization [4]

Core Insights - OPKO Health, Inc. will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco [1] - Management will host one-on-one meetings with investors and present on January 15 at 3:00 p.m. Pacific time, with the presentation available for live webcast and replay [1] Company Overview - OPKO Health is a multinational biopharmaceutical and diagnostics company focused on establishing industry-leading positions in large, rapidly growing markets through its discovery, development, and commercialization expertise [2]

OPKO Health, Inc.’s (OPK) company, ModeX Therapeutics Inc., announced the dosing of the first participant in the Phase I study (NCT06655324) of an Epstein-Barr virus (EBV) vaccine candidate yesterday. The EBV vaccine is being developed in collaboration with Merck, which is known as MSD outside the United States and Canada.Per management, the first participant has been dosed with novel investigational EBV vaccine targeting multiple viral proteins in the Phase I study.It is worth mentioning that this developm ...

Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosisThere are no current treatments or vaccines for EBVFirst participant dosed with novel investigational EBV vaccine targeting multiple viral proteins in Phase I study WESTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), announces dosing of the first participant in the Phase I study (NCT06655324) of an EBV vaccine candidate being ...

Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosisThere are no current treatments or vaccines for EBVFirst participant dosed with novel investigational EBV vaccine targeting multiple viral proteins in Phase I study WESTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), announces dosing of the first participant in the Phase I study (NCT06655324) of an EBV vaccine candidate bein ...

OPKO Health, Inc. (OPK) delivered an earnings per share (EPS) of 3 cents in the third quarter of 2024 against the year-ago period’s loss of 11 cents per share and the Zacks Consensus Estimate of a loss of 10 cents per share.OPK’s Revenues in DetailOPKO Health registered revenues of $173.6 million in the third quarter, down 2.8% year over year. The figure missed the Zacks Consensus Estimate by 4.3%.Lower revenues from products and services dragged the overall top line.Shares of this company gained nearly 4.1 ...

For the quarter ended September 2024, OPKO Health (OPK) reported revenue of $173.6 million, down 2.8% over the same period last year. EPS came in at $0.03, compared to -$0.11 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $181.32 million, representing a surprise of -4.26%. The company delivered an EPS surprise of +130.00%, with the consensus EPS estimate being -$0.10.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wal ...